Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

2.3K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
2.3K
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

74
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
74
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

257
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
257
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

4.7K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.7K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

147
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
147
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

96
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
96

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

11.6K

Antimicrobial stewardship programs - cost-minimizing or cost-effective?

Joyce You1

  • 1School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong , Shatin, NT , Hong Kong joyceyou@cuhk.edu.hk.

Expert Opinion on Pharmacotherapy
|October 22, 2014
PubMed
Summary
This summary is machine-generated.

Antimicrobial stewardship programs (ASPs) show cost savings but their cost-effectiveness is unclear. This editorial discusses barriers to assessing clinical effectiveness and suggests methods for cost-effectiveness analysis of ASPs.

Keywords:
antimicrobial stewardship programcost-effectivecost-minimizingmult-drug resistance

More Related Videos

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
11:52

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

Published on: April 21, 2023

4.1K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K

Related Experiment Videos

Last Updated: Apr 21, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

11.6K
Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
11:52

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

Published on: April 21, 2023

4.1K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K

Area of Science:

  • Health economics
  • Infectious disease management
  • Clinical pharmacy

Background:

  • Antimicrobial stewardship programs (ASPs) are crucial for improving patient care and health outcomes.
  • Existing literature suggests ASP interventions are often cost-saving.
  • However, comprehensive cost-effectiveness data, particularly using quality-adjusted life-years (QALYs), remains limited.

Purpose of the Study:

  • To explore the challenges in evaluating the clinical effectiveness of ASP interventions.
  • To propose strategies for conducting robust cost-effectiveness analyses of ASPs.

Main Methods:

  • Literature review of cost-minimization and cost-effectiveness studies related to ASPs.
  • Discussion of methodological barriers in assessing clinical outcomes and economic value.
  • Synthesis of recommendations for future research.

Main Results:

  • While cost-saving is frequently reported, robust cost-effectiveness data (e.g., cost per QALY) for ASPs is less established.
  • Barriers include difficulties in quantifying clinical benefits and standardizing economic evaluations.
  • The editorial highlights the need for improved methodologies to capture the full value of ASPs.

Conclusions:

  • Further research is needed to overcome barriers in assessing the cost-effectiveness of ASPs.
  • Standardized approaches to cost-effectiveness analysis are essential for demonstrating the value of antimicrobial stewardship.
  • Implementing these recommendations will enhance the evidence base for ASP interventions.